Novavax Covid-19 shot shows 90% efficacy, Serum Institute starts production

On track to make 100 mn doses per month by Q3 of 2021

US based Novavax on Monday said that its nano-particle protein based Covid-19 vaccine candidate has demonstrated an overall 90.4 percent efficacy in phase 3 clinical trials. In India its partner Serum Institute of India (SII) has started manufacturing the vaccine it has named Covovax already.

In fact, the Centre expects availability of 200 mn doses of Covovax between August and December. India will allow entry of this vaccine here once the USFDA approves it.

The vaccine candidate NVX-CoV2373 has shown 100 percent protection against moderate and severe disease, 90.4 percent efficacy overall, and also met the primary endpoint in the